Moxifloxacin in Treating Community Acquired Pneumonia
Abstract
目的 评价莫西沙星治疗社区获得性肺炎(CAP)的临床疗效.方法 66例病人采用随机对照方法分成2组,每组各33例,实验组给予莫西沙星0.4 g口服每天1次,对照组给予左氧氟沙星0.5g口服每天1次,疗程均为7～14d.结果 莫西沙星和左氧氟沙星的总有效率分别为97.0%和90.9%,细菌清除率分别为100%和90.9%,不良反应率分别为6.1%和9.1%.结论 莫西沙星是治疗CAP安全、有效的抗菌药物。
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.